Organization | Cancer Insight, LLC

Cancer Insight, LLC Report issue

For profit Phase 1 Phase 2

Founded: San Antonio TX United States (2000)

Organization Overview

First Clinical Trial

2008

NCT03014076

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Cancer Insight | Cancer Insight, LLC | George E. Peoples

Active Ingredients

Drugs in Phase 2 Trials (13)

briavax (1 trial)

cyclophosphamide (cytoxan) (1 trial)

epacadostat (1 trial)

galinpepimut-s (1 trial)

incmga00012 (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

nelipepimut-s (2 trials)

pembrolizumab (keytruda) (1 trial)

rapamycin (2 trials)

sargramostim (leukine) (2 trials)

sv-br-1-gm (1 trial)

trastuzumab (herceptin) (3 trials)

tumor-pulsed dendritic cells (2 trials)

Drugs in Phase 1 Trials (3)

gm-csf vaccine (1 trial)

gp2 peptide (1 trial)

pallov-cc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenomatous Polyposis Coli (Phase 2)

Breast Neoplasms (Phase 2)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Melanoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 16